Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma

Leslie Calapre, Lydia Warburton, Michael Millward, Mel Ziman, Elin S. Gray

    Research output: Contribution to journalShort surveypeer-review

    80 Citations (Scopus)


    Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. In melanoma, ctDNA has been shown to have clinical value as an alternative tumour source for the detection clinically targetable mutations for the assessment of response to therapy. This review provides a critical summary of the evidence that gives credence to the utility of ctDNA as a biomarker for monitoring of disease status in advanced melanoma and the steps required for its implementation into clinical settings.

    Original languageEnglish
    Pages (from-to)62-69
    Number of pages8
    JournalCancer Letters
    Publication statusPublished - 28 Sep 2017


    Dive into the research topics of 'Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma'. Together they form a unique fingerprint.

    Cite this